The SNMMI Clinical Trials Network provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging radiopharmaceuticals for use in the clinic. Increased standardization in trials leads to better data that then results in expanded utilization of radiopharmaceuticals.
The Clinical Trials Network (CTN) was formed in 2008 by SNMMI to help facilitate the effective use of molecular imaging radiopharmaceuticals in clinical trials. Our Mission is to facilitate the effective use of MI in clinical trials through standardization, coordination, and education for drug development and regulatory approval.
We also maintain a comprehensive database that stores and manages information on imaging sites, production sites, and those sites that have both imaging and production capabilities. To date, we have over 500 sites registered in the CTN database. To access or add your site to the CTN database, click here.
The CTN works with industry partners through the NMCTG, LLC.
The CTN serves a unique and critical function in SNMMI. By working closely with sponsors, associations and agencies, CTN members help to advance key initiatives for standardization in PET/CT clinical imaging. The purpose of the internship program is to identify and train future leaders of SNMMI in the structure, governance and operations of the organization; to prepare individuals for progressive levels of responsibility; and to ensure effective leadership that advances the mission and goals of the organization.
Interns serve a two-year term that begins and ends at the SNMMI Annual Meetings. A mentor is appointed by the CTN Leadership for the intern, to work with the intern and supervise special projects and activities. During the two years, the intern is expected to attend the CTN Leadership and Committee meetings at the SNMMI Mid-Winter and Annual Meetings, and participate in conference calls.
If you are interested is applying for the CTN intern position, please email us at firstname.lastname@example.org.
Patricia Edem, PhD
Patricia Edem, PhD, graduated from McMaster University in Hamilton, Canada, and is currently a radiochemist at BC Cancer. Dr. Edem’s professional interests include radiochemistry, nuclear medicine, molecular imaging, oncology, clinical trials, and clinical translation. She has extensive experience in radiopharmaceutical research in academic and clinical environments, including performing routine quality control and documenting preparation in a GMP environment, establishing radiolabeling methods for several compounds in clinical and preclinical research, and leading the clinical validation for 68Ga-PSMA-11, which resulted in Health Canada approved clinical trial application.
The Clinical Trials Network would like to hear from you.
We are an organization of molecular imaging experts, from physicians and physicists to scientists and technologists. Many are pioneers in the field of nuclear medicine and molecular imaging. If you need assistance in incorporating molecular imaging into a therapeutic trial or want to study a new radiopharmaceutical, our team of experts can assist you with all phases of a clinical trial. From scanner validation, trial design assistance, and study personnel training, the CTN has programs to ensure that you are utilizing molecular imaging effectively and efficiently. To obtain more information about our specific programs or events, please contact us at email@example.com.
A successful scanner validation will ensure that your study patients as well as your clinical patients are being scanned on a qualitatively and quantitatively accurate PET/CT. Contact firstname.lastname@example.org for more info.
CTN works collaboratively with SNMMI Councils and Chapters as well as with external groups to move the entire field forward. In working with other imaging associations such as RSNA, government agencies such as the FDA and industry leaders, the CTN envisions having a key role in advancing the use of radiopharmaceuticals and optimizing the use of molecular imaging in clinical trials and for dissemination into clinical practice.
A successful radionuclide-specific SPECT/CT scanner calibration will allow conversion of the SPECT measured counts/voxel into a true radionuclide concentration measurement (Bq/ml) for accurate dosimetry measurements. Contact email@example.com for more info.
Learn how to interpret imaging agents in our Image Interpretation Modules that include a short didactic background on the tracer and its indication, mechanism of action, normal biodistribution, and discussion of clinical interpretation, including pitfalls, with case reviews by a nuclear medicine expert.
Support for the development of this educational presentation generously provided by the Margie & Robert E. Petersen Foundation.
Click here to find out whats's new in the module.
The CTN sponsors sessions during the SNMMI Mid-Winter and Annual Meetings as well as webinars throughout the year. Clinical research basics remain fairly constant but are often not part of the education and training that many molecular imaging personnel receive. To that end, the CTN has developed an outstanding curriculum covering a wide range of research topics in courses and webinars.
To view all available CTN offerings, go to www.snmmi.org/Education. Scroll down to “Online Education Programs” and select the appropriate link for your credit needs. When the SNMMI Learning Center page opens, type “Clinical Trials Network” in the search box at the top of the page and click the search tool.